Pangaea Data Secures Investment from Topcon Healthcare to Scale AI Platform
Pangaea Data announced an investment from Topcon Healthcare to accelerate the application of Pangaea’s AI platform, which aims to address care gaps in eye health and systemic disease.
Financial terms of the deal were not disclosed.
Pangaea Data’s platform automatically analyzes structured and unstructured patient records against clinical guidelines, emulating a clinician’s manual review, to uncover patients who meet diagnostic or treatment criteria, but are not currently in a treatment or management process. Integrated directly into existing EHR and downstream scheduling systems, the platform enables real-time clinical action without disrupting workflows.
“We are thrilled to partner with Topcon Healthcare to scale our platform’s reach and improve timely diagnosis and treatment across eye care,” said Dr. Vibhor Gupta, Founder and CEO of Pangaea Data. “Together, we can empower providers to close care gaps while generating actionable insights for population health, discovery science, and value-based care.”
Through this partnership, Pangaea Data’s AI platform will leverage Topcon Healthcare’s Harmony digital health platform, creating an interface for optometry and ophthalmology practices to identify patients needing follow-up or further evaluation. This includes patients with conditions such as glaucoma, 50% of whom remain undiagnosed in the US, and diabetic retinopathy, where more than one-third of diagnosed diabetics do not receive their recommended annual eye screening.
“Pangaea Data’s unique ability to find missed patients using AI, and to do so without burdening clinicians, has powerful implications for eye care and beyond,” said Ali Tafreshi, CEO & President of Topcon Healthcare. “This partnership supports our Healthcare from the Eye initiative, which uses ocular data and AI to transform how systemic and ocular diseases are detected and managed. We are proud to support Pangaea Data’s mission through this strategic investment.”
Pangaea Data’s platform has already demonstrated impact across multiple therapeutic areas, including pulmonology, cardiology, oncology, nephrology, and infectious diseases.